News and Announcements
Insync Funds Significantly Outperforms Benchmark | May Update
- Published June 21, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
We are pleased to report that both the Insync funds significantly outperformed the benchmark again in May. The Global Capital Aware fund delivered in excess of +19% over the benchmark for the year, benefitting from the downside protection and strong focus on quality businesses. Our long-only Global Quality Equity fund was +14% over benchmark. Both consistently outperformed in both rising and falling markets over the past 5 months through some of the most volatile times in a century.
We continue holding companies exposed to Megatrends that our work shows will deliver sustainable profitable growth in a post pandemic environment. Insync is a broad-based global equity fund exposed to 16 such global Megatrends with each business delivering very high levels of profitability (ROIC), and are on the right side of disruption. Beneficiaries extend well beyond technology, the Amazon’s and the Alphabet’s of the world, and into areas like pet nutrition, animal diagnostics, medical devices businesses, beauty and athleisure.
To read the full article, click here.
About Insync Funds Management Pty Ltd
Insync Funds Management Pty Ltd is a Sydney-based specialist future focused global equity funds management company established in 2009 that invests in a concentrated portfolio of highly profitable global stocks that have delivered superior returns for our fund investors over a sustained period of 10 years.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
